Taysha Gene Therapies is a brand dedicated to the discovery, development, and commercialization of gene therapies for the treatment of monogenic diseases of the central nervous system (CNS). They are committed to eradicating these diseases and improving the lives of patients. Taysha Gene Therapies was founded in partnership with The University of Texas Southwestern Medical Center (UT Southwestern), which brings together the collective expertise of researchers, clinicians, and investigators with decades of experience in cutting-edge research and clinical care.

This partnership allows Taysha to leverage UT Southwestern's faculty, GMP viral vector manufacturing facility, and integrated research and clinical care approach. The brand's team consists of accomplished gene therapy scientists and CNS disease experts who share a patient-first focus. With their expertise and dedication, they are pioneering transformative therapies that have the potential to bring new cures to life.

Taysha Gene Therapies is rooted in the heart of Dallas, Texas, where the legacy of hardworking pioneers fuels their trailblazing mindset. They strive to continue the legacy of exploration and innovation that has shaped the state's history. With a strong partnership, a talented team, and a commitment to patients, Taysha Gene Therapies is at the forefront of developing gene therapy treatments that can revolutionize the field of CNS disease treatment